Synopsis: India’s speciality chemical sector has faced weak demand and Chinese price pressure in recent quarters. Yet amid this slowdown, institutions have steadily increased holdings in Clean Science & Technology Ltd, signalling smart money may be positioning for the next upcycle rather than focusing on near-term profit weakness.
India’s speciality chemicals industry has been navigating one of its toughest phases in recent years. Global demand has remained sluggish, customers have continued inventory correction, and Chinese manufacturers have responded with aggressive price cuts across several product categories. As a result, many listed chemical companies have reported muted topline growth and pressure on profitability. However, while sector sentiment has remained cautious, ownership trends in the speciality chemical stock suggest a different story may be unfolding.
With a market capitalisation of ₹8,705 crores, the shares of Clean Science and Technology Limited closed at ₹819 a piece in Thursday’s trading session at a slightly lower price compared to its previous day close of Rs. 822.65. The stock has corrected by 29.72 percent over the last 1 year. However, over the past month, the stock has moved up by 17.28%
Institutional Buying Despite Weak Earnings
Over the last three years, foreign institutional investors have steadily increased their stake in Clean Science & Technology from around 4% to 13%. Domestic institutional investors have simultaneously raised their holdings from 4% to 17%. Combined institutional ownership now exceeds 30%, built almost entirely during a period of earnings pressure and sector-wide weakness.
Such accumulation during a downcycle is worth paying attention to. Institutions typically position early when they see medium-term recovery potential rather than reacting to current quarter numbers.
Why Clean Science May Be Standing Out
Unlike broad-based chemical manufacturers, Clean Science focuses on niche performance chemicals where process efficiency and product purity create meaningful barriers to entry. Its portfolio includes MEHQ, BHA, TBHQ, HALS, and Anisole, products where the company holds a top-three global position in terms of manufacturing capacity.
Commodity chemical businesses tend to suffer sharper margin compression when supply exceeds demand. Niche players with specialised products and captive process chemistry tend to retain better profitability through the cycle. Clean Science’s EBITDA margins have stayed above 40% for eight consecutive quarters, through some of the most difficult conditions the sector has seen.
Expansion Signals Confidence: The CapEx and HALS
Apart from launching new products, the company is expanding its performance chemicals segment through a capex plan of around ₹150 crore. This includes a new facility named Performance Chemical 2, expected to commence operations by June 2026.
HALS has become one of the primary growth drivers for the company. During Q3FY26, revenue from the HALS segment grew by a strong 55% YoY, supported by a better product mix and cost-efficient polymer inputs. The company also commercialised a new hydroquinone and catechol plant during the quarter, which management expects to support margins.
HALS is used in polymer protection applications and is considered a higher-value segment. If demand conditions improve globally, these new capacities could potentially support a stronger earnings rebound than the market currently expects. This suggests FIIs and DIIS may not be buying present numbers; they may be buying future operating leverage.
A New Risk: China’s Sulphuric Acid Ban
China has confirmed a halt on sulphuric acid exports from May 2026, with prices already more than doubling since March. Since sulphuric acid is a key input in hydroquinone production, central to Clean Science’s process, sustained price elevation could pressure margins the company has defended above 40% through the downcycle. A new variable worth watching in quarterly results.
Valuation Still Matters
The stock trades at a price-to-earnings multiple of 32x, a modest premium to the industry median of 28.7x. The PEG ratio at 3.8x is elevated relative to peers, reflecting the near-term earnings weakness and premium assigned to the quality of the business.
That means expectations are already partially built in. If global demand recovery takes longer than anticipated, or if Chinese pricing pressure persists, the re-rating may remain limited despite strong underlying fundamentals. Investors entering at current levels need to be comfortable with the earnings recovery timeline remaining uncertain.
So, Why Are Both FIIs and DIIs Still Buying?
Because they may be looking beyond current earnings and positioning for the next upcycle. A decade of strong profit compounding, EBITDA margins above 40% even during a downturn, and new high-value capacities coming online strengthen the medium-term case. If demand normalises and pricing pressure eases, Clean Science could be among the better-placed players in the sector recovery.
Market Takeaway
Clean Science appears to be a case where ownership trends are improving before earnings fully recover. The company’s niche positioning, strong balance sheet, and expanding capacity base give it the ingredients for a meaningful rebound when conditions normalise. The sulphuric acid overhang and promoter stake reduction are genuine risks that sit alongside the institutional conviction story, and both deserve equal weight. Going forward, Investors can track quarterly margin trends, new capacity ramp-up, and institutional holding patterns to gauge when the thesis begins converting into earnings.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Chemical Stock Where FIIs and DIIs Ignored Its Profit Dip and Increased Their Stake from 4% to 17% appeared first on Trade Brains.